JP5017103B2 - 薬剤共結晶組成物および関連した使用方法 - Google Patents

薬剤共結晶組成物および関連した使用方法 Download PDF

Info

Publication number
JP5017103B2
JP5017103B2 JP2007516812A JP2007516812A JP5017103B2 JP 5017103 B2 JP5017103 B2 JP 5017103B2 JP 2007516812 A JP2007516812 A JP 2007516812A JP 2007516812 A JP2007516812 A JP 2007516812A JP 5017103 B2 JP5017103 B2 JP 5017103B2
Authority
JP
Japan
Prior art keywords
crystal
acid
carbamazepine
degrees
angstrom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007516812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008503495A (ja
Inventor
マクマホン，ジエニフアー
ピーターソン，マシユー
ザウオロトコ，マイケル・ジエイ
シヤトツク，タニセ
ブアゴル，ヒツキー・マガリ
Original Assignee
トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド
ユニバーシテイ・オブ・サウス・フロリダ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド, ユニバーシテイ・オブ・サウス・フロリダ filed Critical トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド
Publication of JP2008503495A publication Critical patent/JP2008503495A/ja
Application granted granted Critical
Publication of JP5017103B2 publication Critical patent/JP5017103B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
JP2007516812A 2004-06-17 2005-06-16 薬剤共結晶組成物および関連した使用方法 Expired - Fee Related JP5017103B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US58066104P 2004-06-17 2004-06-17
US60/580,661 2004-06-17
US58580804P 2004-07-06 2004-07-06
US60/585,808 2004-07-06
US62148504P 2004-10-22 2004-10-22
US60/621,485 2004-10-22
US62870104P 2004-11-17 2004-11-17
US60/628,701 2004-11-17
PCT/US2005/021662 WO2006007448A2 (en) 2004-06-17 2005-06-16 Pharmaceutical co-crystal compositions and related methods of use

Publications (2)

Publication Number Publication Date
JP2008503495A JP2008503495A (ja) 2008-02-07
JP5017103B2 true JP5017103B2 (ja) 2012-09-05

Family

ID=35784343

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007516812A Expired - Fee Related JP5017103B2 (ja) 2004-06-17 2005-06-16 薬剤共結晶組成物および関連した使用方法

Country Status (4)

Country Link
US (1) US7803786B2 (US07803786-20100928-C00028.png)
EP (1) EP1765379A4 (US07803786-20100928-C00028.png)
JP (1) JP5017103B2 (US07803786-20100928-C00028.png)
WO (1) WO2006007448A2 (US07803786-20100928-C00028.png)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
WO2006116473A1 (en) * 2005-04-27 2006-11-02 Transform Pharmaceuticals, Inc. Novel polymorph of acetylsalicylic acid, and methods of making and using the same
EP1991229A2 (en) * 2006-02-27 2008-11-19 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
CA2668464A1 (en) * 2006-11-02 2008-06-19 University Of South Florida Materials and methods for co-crystal controlled solid-state synthesis of imides and imines
TW200901889A (en) 2007-02-09 2009-01-16 Basf Se Crystalline complexes of agriculturally active organic compounds
AU2008219607B2 (en) * 2007-02-27 2013-09-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
US8318789B2 (en) * 2007-03-23 2012-11-27 Syngenta Limited Co-crystals of propiconazole
GB0706044D0 (en) * 2007-03-28 2007-05-09 Syngenta Ltd C0-Crystals
WO2008153938A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Epigallocatechin-3-gallate crystal compositions
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
DE102007030695A1 (de) * 2007-07-01 2009-01-08 Sciconcept Gmbh Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten
ATE530546T1 (de) * 2007-08-30 2011-11-15 Vertex Pharma Kokristalle und pharmazeutische zusammensetzungen damit
GB0813709D0 (en) * 2008-07-26 2008-09-03 Univ Dundee Method and product
WO2010020856A2 (en) * 2008-08-19 2010-02-25 Adcock Ingram Healthcare (Pty) Limited Rate modulated delivery of drugs from a composite delivery system
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
BRPI0923504A2 (pt) * 2008-12-11 2020-05-26 Axcentua Pharmaceuticals Ab Formas cristalinas de genisteína.
US8586587B2 (en) * 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011036676A2 (en) * 2009-09-23 2011-03-31 Ashwini Nangia Stable cocrystals of temozolomide
WO2011054741A2 (en) * 2009-11-06 2011-05-12 Basf Se Crystalline complexes of 4-hydroxy benzoic acid and selected pesticides
WO2011115069A1 (ja) * 2010-03-19 2011-09-22 第一三共株式会社 結晶の網羅的探索
MX339570B (es) 2010-05-11 2016-05-31 Janssen Pharmaceutica Nv Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienil-metilbenceno como inhibidores de transportadores de glucosa dependientes de sodio.
WO2011153444A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof
UA109290C2 (uk) * 2010-10-07 2015-08-10 Спільні кристали і солі інгібіторів ccr3
CA2831086A1 (en) * 2011-03-24 2012-09-27 University Of South Florida Lithium compositions
CN103288724A (zh) * 2013-05-31 2013-09-11 天津大学 一种氟尼辛与卡马西平共晶及其制备方法
US20150080567A1 (en) 2013-09-04 2015-03-19 Nalas Engineering Services Inc. Method to Produce and Scale-Up Cocrystals and Salts Via Resonant Acoustic Mixing
GB201411802D0 (en) 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
US9879038B2 (en) * 2014-07-18 2018-01-30 Jw Pharmaceutical Corporation Salt of tenofovir disoproxil
JP6830058B2 (ja) 2015-03-02 2021-02-17 武田薬品工業株式会社 ナノ共結晶を含有する懸濁液または組成物およびこれらの製造方法
CN109563024B (zh) 2016-06-13 2023-06-06 心悦生医股份有限公司 苯甲酸锂的共晶及其用途
KR102403048B1 (ko) 2016-06-13 2022-05-26 신유알엑스 인터내셔널 (타이완) 코포레이션 벤조산나트륨의 공-결정 및 그의 용도
JP2019524894A (ja) * 2016-08-19 2019-09-05 セルジーン インターナショナル ツー エスアーエールエル マリゾミブのモルフィック形態およびその使用
WO2018117177A1 (ja) 2016-12-21 2018-06-28 小野薬品工業株式会社 Ｂｒｋ阻害化合物
EP3581569A4 (en) 2017-02-08 2020-02-19 ONO Pharmaceutical Co., Ltd. CONNECTION WITH AGONISTIC SOMATOSTATIN RECEPTOR ACTIVITY AND PHARMACEUTICAL USE THEREOF
US11479550B2 (en) 2017-05-22 2022-10-25 Ono Pharmaceutical Co., Ltd. EP4 antagonist
TWI789495B (zh) 2018-02-22 2023-01-11 日商小野藥品工業股份有限公司 具有ｓ1ｐ5受體作動活性的化合物
KR102425709B1 (ko) 2018-09-20 2022-07-28 오노 야꾸힝 고교 가부시키가이샤 Dp 길항제
TW202028212A (zh) 2018-10-11 2020-08-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
CN109796393A (zh) * 2019-01-25 2019-05-24 云南开放大学 一种吡拉西坦共晶及其制备方法
TW202114985A (zh) 2019-06-28 2021-04-16 日商小野藥品工業股份有限公司 Ｅｐ拮抗劑
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
JPWO2021107125A1 (US07803786-20100928-C00028.png) 2019-11-29 2021-06-03
EP4134134A4 (en) 2020-04-10 2023-12-27 ONO Pharmaceutical Co., Ltd. STING AGONIST COMPOUND
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법
IL297900A (en) 2020-05-07 2023-01-01 Ono Pharmaceutical Co A compound with kdm5 inhibitory activity and its pharmaceutical use
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
AU2022251752A1 (en) 2021-04-01 2023-10-12 Ono Pharmaceutical Co., Ltd. Abhd6 antagonist
CN113845438B (zh) * 2021-10-12 2023-02-21 河北大学 一种对乙酰氨基酚-吡拉西坦药物共晶及其制备方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
DE2256979C3 (de) * 1972-11-21 1981-05-21 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Benzolsulfonylharnstoffen
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
FI95269C (fi) * 1989-05-15 1996-01-10 Squibb Bristol Myers Co 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja
US6207650B1 (en) * 1989-05-15 2001-03-27 Bristol-Myers Squibb Company Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5780058A (en) * 1995-07-21 1998-07-14 Alza Corporation Oral delivery of discrete units
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
AU1623099A (en) * 1997-12-22 1999-07-12 Alza Corporation Rate controlling membranes for controlled drug delivery devices
JP4173635B2 (ja) * 1997-12-29 2008-10-29 インターシア セラピューティクス，インコーポレイティド 膜プラグ保持機構を有する浸透供給装置
ATE322928T1 (de) * 1997-12-31 2006-04-15 Alza Corp Verfahren zur überwachung einer osmotischen wirkstoffabgabevorrichtung
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US6635753B1 (en) * 1998-09-30 2003-10-21 Brantford Chemicals Inc. Process for the preparation of substantially pure stavudine and related intermediates useful in the preparation thereof
NZ511465A (en) * 1998-11-02 2003-10-31 Alza Corp Controlled delivery of active agents
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
US6559293B1 (en) * 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
AU2003213719A1 (en) * 2002-03-01 2003-09-16 Regents Of The University Of Michigan Multiple-component solid phases containing at least one active pharmaceutical ingredient
EP1511490A4 (en) * 2002-05-31 2009-03-11 Transform Pharmaceuticals Inc NOVEL CONAZOLE CRYSTALLINE FORMS AND RELATED METHODS, PHARMACEUTICAL COMPOSITIONS AND METHODS
CA2514092C (en) * 2003-01-21 2013-03-19 S.S.C.I., Inc. Novel cocrystallization of hydrochloric acid salt of an active agent
CA2514733A1 (en) * 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen

Also Published As

Publication number Publication date
EP1765379A2 (en) 2007-03-28
US7803786B2 (en) 2010-09-28
WO2006007448A3 (en) 2007-10-25
US20070299033A1 (en) 2007-12-27
EP1765379A4 (en) 2009-05-27
JP2008503495A (ja) 2008-02-07
WO2006007448A2 (en) 2006-01-19

Similar Documents

Publication Publication Date Title
JP5017103B2 (ja) 薬剤共結晶組成物および関連した使用方法
JP4923182B2 (ja) セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物
US7671093B2 (en) Mixed co-crystals and pharmaceutical compositions comprising the same
US20070026078A1 (en) Pharmaceutical co-crystal compositions
US20070059356A1 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2004078163A2 (en) Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US20100311701A1 (en) Pharmaceutical Co-Crystal Compositions
CA2534664C (en) Modafinil compositions
WO2005089511A2 (en) Novel pharmaceutical forms, and methods of making and using the same
US8809586B2 (en) Modafinil compositions
AU2005212229A1 (en) Modafinil compositions
US7566805B2 (en) Modafinil compositions
US7186863B2 (en) Sertraline compositions
EP2292213A1 (en) Compositions comprising a polymorphic form of armodafinil
JP4842819B2 (ja) モダフィニル組成物
ALMARSSON et al. Patent 2514733 Summary
ZA200602736B (en) Modafinil compositions
NZ548656A (en) A polymorph of R-(-)-modafinil, for use in treating sleep and other disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080610

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20080828

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080828

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090113

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20110331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110719

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110726

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110822

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120605

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120611

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150615

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5017103

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees